This is the “exciting” time of year when the PBM Drug Trend Reports come out. With the exception of last year, I’ve reviewed them every year. I reviewed the 2013 Express Scripts Drug Trend Report the other day, and I’ll try to do both the CVS Caremark and the CatamaranRx reports this week. The only one I’m still waiting to see is the Prime Therapeutics report. And, as far as I know, there aren’t any other PBMs that publish reports annually. (but please correct me if I’m wrong)
I’ll reiterate several points:
- The methodologies used by each PBM can and may vary. Therefore, these are not necessarily perfect comparisons.
- I would question whether trend is the right metric in isolation to view the PBM. (more to come in another post on PBM differentiation)
- The client mix by PBM does matter (see chart below from the CVS Caremark report this year which shows the differences by client type).
Here are the summaries from the 3 Drug Trend Reports showing the trend in PMPM costs based on traditional categories, specialty medications, and an overall trend.